

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/550,663	First Named Inventor: WEI, Zhongyong	
371 Filing Date: 09/26/2005	Attorney Docket No.: 101022-1P US	
Examiner: RAHMANI, N.	Group Art Unit: 1625	
Customer No.: 22466	Confirmation No.: 3011	
Title: Azaindole Derivatives, Preparations Thereof, Uses Thereof and Compositions		
Containing Them		

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

Applicants want to inform the Examiner that these references were first filed in the USPTO in a previous IDS on January 3, 2006 in the instant application, and a copy of the postcard acknowledging the receipt of the previous IDS is attached herewith. However, the consideration of the references cited in that particular IDS were never acknowledged by the Examiner. Applicants hereby cite these references for the second time and respectfully request the Examiner to consider these references during the examination of the instant application.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

X (1)	within three	e (3) months of the filing date of a national application other than a
	continued	prosecution application under 37 C.F.R. 1.53(d), or within three (3) months
	of the date	of entry of the national stage as set forth in 37 C.F.R. 1.491 in an
	internation	al application, or before the mailing of the first Office Action on the
	merits, or t	pefore the mailing of a first Office Action after the filing of a request for
	continued	examination under 37 C.F.R. 1.114; or
<u>(2)</u>	after the pe	eriod defined in (1) but before the mailing date of a final Action or a
	Notice of	Allowance under 37 C.F.R. 1.311, and
		the requisite Statement is below, OR
		the Commissioner is hereby authorized to charge the requisite fee
		under 37 C.F.R. 1.17(p), namely \$180.00 to deposit account No.
		, referencing Attorney Docket No. , or
(3)	after the m	ailing date of a final Action or Notice of Allowance but before the
	payment o	f the Issue Fee, AND
		the requisite Statement is below, AND
		the Commissioner is hereby authorized to charge the requisite fee
		under 37 C.F.R. 1.17(p), namely \$180.00 to deposit account No.
		, referencing Attorney Docket No. , or

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101022-1P US.

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076/

Name: Jianzhong Shen Dated: December 21, 2007

Reg. No.: 48,076

Phone No.: 302-886-8854

Global Intellectual Property, Patents,

AstraZeneca 1800 Concord Pike Wilmington

DE-19850-5437

Enclosure:

A return postcard acknowledging the receipt of the previous IDS filed on Jan. 3, 2006.

By date stamping and returning this card, the USPTO acknowledges the receipt of:

1. Transmittal Form (1 pg)

2. Information Disclosure Statement (2 pgs)

3. Form PTO/SB/08A (1 pg)

4. References (2)

5. Return Receipt Postcard

Applicant: Wei et al. Mailed: January **3**, 2006 Docket No. 101022-1P US

DSH/ea

IAP3 Res'dPOTIFTO 10 JAN 2006

• •
: